Jain Global’s Summit Therapeutics SMMT Stock Holding History

Jain Global’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,786	Closed	-$205K	–	2019
2026 Q1	$205K	Buy	+10,786	New	+$174K	﹤0.01%	1087
2025 Q3	–	Sell	-87,943	Closed	-$1.87M	–	1455
2025 Q2	$1.87M	Buy	+87,943	New	+$2.01M	0.01%	517

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Jain Global's SMMT Position: Q2 2026 in Review

Jain Global sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 10,786 shares — an estimated $205K sold.

Jain Global first reported a position in SMMT in Q2 2025 and held it in 2 quarters. The position peaked at $1.87M in Q2 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Jain Global reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
Jain Global sold 10,786 Summit Therapeutics shares in Q2 2026, an estimated $205K.
Jain Global first reported a position in Summit Therapeutics in Q2 2025 and held it in 2 quarters.
Jain Global's Summit Therapeutics position peaked at $1.87M in Q2 2025.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Jain Global's 13F filing for Q2 2026, filed 14 Aug 2026.